Pharmacokinetic Study of a Novel Cannabidiol (CBD) Formulation in Healthy Volunteers

NCT07186283 | Completed Phase 1

• 1 other identifier: NWPharma_CH_001
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to test a new formulation of cannabidiol (CBD) to see how it is processed in the body and how safe it is for healthy volunteers. CBD is a compound found in the cannabis plant that has shown potential to help treat various medical and mental health conditions. While there is already an approved CBD-based drug that is used for epilepsy in the UK, called Epidyolex, most CBD formulations have poor absorption when taken orally, reducing their effectiveness and often requiring higher doses. NW PharmaTech has developed a new CBD formulation aimed at improving absorption and processing by the body. This study will assess the absorption, safety, and tolerability of two different doses (600 mg and 900 mg) of the new formulation and will compare them with Epidyolex (dosed as per approved label). All participants will receive each of the following three dosing regimens in a randomised order across three separate experimental periods, with each period separated by a 25 day washout period, which ensures that the drug from one dosing regimen is fully cleared from your body before the next dosing regimen begins. Regimen A: 600 mg of the new CBD formulation (NW300EMCBD) administered orally Regimen B: 900 mg of the new CBD formulation (NW300EMCBD) administered orally Regimen C: 25 mg/kg Epidyolex solution (2 x 12.5 mg/kg doses separated by 12 hours) administered orally In total, participants will complete three dosing visits (one per experimental period), each spaced 25 days apart. The study will evaluate the pharmacokinetics (PK) of the formulations, which refers to how the body absorbs, distributes, metabolizes, and eliminates the drugs.

Conditions

PK in Healthy Volunteers

Keywords

Cannabidiol formulation; Cannabidiol pharmacokinetic; Encapsulated Micellar CBD formulation; Cannabidiol safety

Outcome Measures

Primary Outcomes (1)

• CBD plasma concentration

  Difference in CBD plasma concentration between the novel formulation and Epidyolex

  Pre-dose up to 192 hours post dose

Secondary Outcomes (18)

• Total Area Under the Curve (AUCinf)

  Pre-dose up to 192 hours post dose

• Total Area Under the Curve (AUCt)

  Pre-dose up to 192 hours post dose

• Dose-normalised Total Area Under the Curve (AUCinf/D)

  Pre-dose up to 192 hours post dose

• Cmax

  Pre-dose up to 192 hours post dose

• Tmax

  Pre-dose up to 192 hours post dose

Other Outcomes (2)

• Change in VAMS subscales (mental sedation subscale, tranquilisation and calming effects subscale, physical sedation subscale, other feelings and effects subscale)

  Pre-dose to 3 hours post dose

• Change in the Drug Experience Questionnaire (DEQ-5)

  Pre-dose to 3 hours post dose

Study Arms (3)

NW300EMCBD 600 mg

EXPERIMENTAL

600 mg CBD soft-gel capsules (novel formulation)

Drug: CBD soft-gel capsules 600 mg

NW300EMCBD 900 mg

EXPERIMENTAL

900 mg CBD soft-gel capsules (novel formulation)

Drug: CBD soft-gel capsules 900 mg

Epidyolex

ACTIVE COMPARATOR

25 mg/kg

Drug: Epidyolex

Interventions

CBD soft-gel capsules 900 mg DRUG

900 mg

NW300EMCBD 900 mg

Epidyolex DRUG

25 mg/kg

Epidyolex

CBD soft-gel capsules 600 mg DRUG

600 mg

NW300EMCBD 600 mg

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female volunteers.
• Age range between 18 and 55 years old.
• Weight at least 50kg and have a body mass index (BMI) between 19 and 30 kg/m2 at screening.
• Willingness to comply with and complete all study procedures, including consuming the protocol specified high-fat, high-calorie meal in 30 minutes.
• In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory evaluations at screening and check-in, and from the physical examination at screening and symptom-directed physical examination at baseline, as assessed by the investigator or designee.
• Abstinence from consuming St John's wort, grapefruit (juice), alcohol or tobacco and nicotine products for at least 72 hours prior to dosing and throughout treatment period.
• Abstinence from caffeine for the duration of the in-clinic confinement period, including all dosing days. Caffeinated beverages and products will not be available on site.
• Capable and willing to comply with protocol requirements during the study.
• Participant is willing and able to give informed consent for participation in the study.

You may not qualify if:

• Participation in a research clinical trial within 90 days prior to Day 1 of the first experimental period, or 5 elimination half-lives prior to Day 1 of the first experimental period (whichever is longer) to Day 1, or throughout the study.
• Use of cannabis products, including hemp, in any form (including medication, oils, edibles or drinks) during the last 28 days before screening.
• History of hypersensitivity or allergy to CBD oil, sesame oil, hemp or any other cannabinoid products, or any of the items that could be included in the standardized meals/snacks.
• Using any regular medication in the 28 days prior to screening and throughout the study (as required doses of paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) are permitted).
• Abnormal screening sample: clinically significant liver, renal or haematological abnormalities, including total Bilirubin, ALT or AST \> the upper limit of normal (ULN).
• Positive screening test indicating active infection with HIV, hepatitis B virus or hepatitis C virus. Participants with evidence of past HBV infection and complete recovery may be eligible, at the discretion of the Investigator, provided liver function tests are within normal limits and there is no evidence of active infection.
• Positive urine drug sample, including THC, at screening and, baseline excluding THC at post-dose.
• Positive alcohol breathalyser test at screening and throughout the study.
• Any suicidal ideation or behaviour in the past 12 months as assessed by responses to Columbia Suicidal Severity Rating questionnaire at screening.
• Any history of mental disorder including major depressive disorder, bipolar disorder, psychosis, and any current substance use disorder, including alcohol and tobacco use disorder.
• Any self-reported, observed or assessed medical condition that might put the subject at risk according to the physician's opinion.
• Any significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data.
• Participants with a sitting blood pressure at screening, after resting for 5 minutes, higher than 140/90 mmHg or lower than 90/50 mmHg.
• Blood donation or loss (eg surgery) over 200 ml in 3 months prior to screening and throughout study (menstruation is acceptable).
• Male participants not willing to use contraceptive methods throughout the study.

Sponsors & Collaborators

• NW PharmaTech Ltd: lead

Study Sites (1)

Fortrea Clinical Research Unit (Drapers Yard)

Leeds, West Yorkshire, LS11 9EH, United Kingdom

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 5, 2025
• First Posted: September 22, 2025
• Study Start: September 22, 2025
• Primary Completion: December 10, 2025
• Study Completion: December 10, 2025
• Last Updated: February 2, 2026

Record last verified: 2025-09

Locations

GB (1)